Pathophysiology of graft-versus-host disease
JLM Ferrara, P Reddy - Seminars in hematology, 2006 - Elsevier
Complications of allogeneic hematopoietic stem cell transplantation (HSCT) remain barriers
to its wider application for a variety of diseases. Graft-versus-host disease (GVHD) is the …
to its wider application for a variety of diseases. Graft-versus-host disease (GVHD) is the …
Current therapy for multiple myeloma
SV Rajkumar, MA Gertz, RA Kyle, PR Greipp… - Mayo Clinic …, 2002 - Elsevier
Multiple myeloma is an incurable plasma cell malignancy that accounts for 10% of all
hematologic cancers. For decades the mainstay of therapy has been the use of melphalan …
hematologic cancers. For decades the mainstay of therapy has been the use of melphalan …
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
R Diaconescu, CR Flowers, B Storer, ML Sorror… - Blood, 2004 - ashpublications.org
Nonmyeloablative regimens for allogeneic hematopoietic cell transplantation (HCT) have
been developed for patients ineligible for myeloablative conditioning. We compared …
been developed for patients ineligible for myeloablative conditioning. We compared …
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney, AJ Molina, F Sahebi… - Blood, 2003 - ashpublications.org
The full potential of a graft-versusmyeloma effect after allogeneic hematopoietic cell
transplantation (HCT) for patients with multiple myeloma (MM) has not been realized …
transplantation (HCT) for patients with multiple myeloma (MM) has not been realized …
Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning …
ML Sorror, MB Maris, B Storer, BM Sandmaier… - Blood, 2004 - ashpublications.org
We have carried out HLA-matched unrelated donor hematopoietic cell transplantation (HCT)
after nonmyeloablative conditioning in patients with hematologic malignancies who were …
after nonmyeloablative conditioning in patients with hematologic malignancies who were …
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the …
C Crawley, M Lalancette, R Szydlo, M Gilleece… - Blood, 2005 - ashpublications.org
We report the outcome of 229 patients who received an allograft for myeloma with reduced-
intensity conditioning (RIC) regimens from 33 centers within the European Group for Blood …
intensity conditioning (RIC) regimens from 33 centers within the European Group for Blood …
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
P Corradini, M Cavo, H Lokhorst, G Martinelli… - Blood, 2003 - ashpublications.org
Patients in complete clinical remission after myeloablative allogeneic stem cell
transplantation (allo-SCT) were enrolled in a longitudinal study to assess the predictive …
transplantation (allo-SCT) were enrolled in a longitudinal study to assess the predictive …
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low …
N Kröger, HG Sayer, R Schwerdtfeger… - Blood, The Journal …, 2002 - ashpublications.org
We investigated the feasibility of unrelated stem cell transplantation in 21 patients with
advanced stage II/III multiple myeloma after a reduced-intensity conditioning regimen …
advanced stage II/III multiple myeloma after a reduced-intensity conditioning regimen …
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation
J Casper, W Knauf, T Kiefer, D Wolff, B Steiner… - Blood, 2004 - ashpublications.org
New conditioning regimens are being explored to reduce toxicity and enable allogeneic
bone marrow transplantation in patients not eligible for conventional transplantation. We …
bone marrow transplantation in patients not eligible for conventional transplantation. We …
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non …
L Farina, B Bruno, F Patriarca, F Spina, R Sorasio… - Leukemia, 2009 - nature.com
The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been
developed to identify patients at high risk of mortality after an allograft. Reduced …
developed to identify patients at high risk of mortality after an allograft. Reduced …